Choose modality
Separate transcript, nanoparticle, oligo and vector control logic from the start.
RNAOS Platform
Plan, analyze, govern and connect RNA development evidence.
RNAOS helps RNA and advanced-therapy teams decide what to measure, execute purpose-built analytical workflows, preserve how each result was produced, compare evidence across runs and methods, and generate reviewable outputs without losing provenance.
PlanTurn modality, stage and regulatory context into an analytical and CMC roadmap.
AnalyzeRun scientific workflows across RNA, particles, oligos, sequencing, formulation and stability.
GovernPreserve source, versions, parameters, review, signatures, audit and reports.
ConnectCompare assays, samples, lots, formulations and programs in one evidence model.
End-to-end product journey
The context does not disappear when the calculation starts.
RNAOS carries modality, stage and program decisions into assay execution, governed evidence and report generation.
Frame the programOrganization, project, modality, stage and product architecture.
Map the strategyCQAs, DS/DP control logic, method intent and evidence gaps.
Execute scienceSupported source files or controlled inputs with versioned logic.
Preserve evidenceChecksums, parameters, versions, results, warnings and lineage.
Review & reportComparisons, approval patterns, governed reports and exports.
Modality-aware planning
Guide teams into the right scientific and regulatory logic.
RNAOS distinguishes mRNA-LNP, siRNA-LNP, GalNAc oligos, IVT RNA, viral-vector and broader ATMP programs instead of presenting one generic assay menu.
Apply the stage lens
Shift recommendations between discovery, IND-enabling, clinical and PPQ-readiness contexts.
Execution
Purpose-built workflows across drug substance, drug product and QC.
Users see the relevant analytical modules for their product architecture and stage, while the evidence lane stays visible.
Drug substance assays
Identity, integrity, capping, transcription impurities, Poly(A), oligo purity and vector architecture.
Drug product assays
Encapsulation, particle size, charge, integrity, residual solvents, potency and packaged species.
QC, release and stability
Method planning, stability intelligence, reports, audit trails, connectors and governed review.
Evidence
Controlled comparison, reporting and quality decisions.
Cross-assay workspaces turn individual runs into a connected evidence model while preserving source-to-result reconstruction.
Platform breadth
One platform for planning, analytics, quality and reporting.
RNAOS connects analytical workflows, planning, governed records, quality specifications, reporting and integrations so scientific context stays connected from development through review.
A
Analytical depth
Particle size, encapsulation, RNA integrity, capping, Poly(A), DLS/MALS, RiboGreen, oligo analytics, NGS, viral vectors and stability.
D
Development intelligence
CMC strategy, developability, QC method planning, formulation, scale-up, technology transfer, eCTD gaps, nonclinical and clinical planning.
Q
Governance & operations
Samples, projects, batches, runs, specifications, audit, review, reports, validation operations, integrations, subscriptions and permissions.
Start with RNAOS
Pilot RNAOS with a workflow that matters to your team.
A focused 6–8 week pilot uses your representative data to evaluate calculations, provenance, review, reporting and workflow handoffs in a real use case.